Press Release

NEMOD Biotherapeutics: successful completion of biodistribution studies for KaroMab™

Berlin, 07.10.2003. NEMOD Biotherapeutics GmbH & Co KG, a biopharmacutical company focusing on oncological indications, announced successful completion of preclinical biodistribution studies for the systemic delivery of the company's proprietary product KaroMab™. The monoclonal antibody that targets the Thomsen-Friedenreich antigen solely found in tumors accumulates strongly and specifically in colon and breast carcinomas implanted in mice.

"With this preclinical study we have been able to obtain a second antibody candidate for clinical development besides our lead product PankoMab™", said Dr. Andreas Hey, COO of NEMOD Biotherapeutics GmbH & Co. KG. "Together with a highly specific antibody against Lewis Y in preclinical development we now have a strong tumor antibody portfolio for outlicensing to strategic partners."

In this biodistribution study different antibody formats of KaroMab™ were radiolabelled with 111-Indium and injected in mice xenografted with colon and breast tumor implants. The measurement of 111-Indium uptake in several organs and the tumor revealed that about 10% of the injected dose per gram accumulated in the tumor. The remainder of the antibody rapidly cleared off the circulation, associated with a renal load as expected decreasing with the size of the antibody format.

NEMOD Biotherapeutics GmbH & Co. KG ( is a drug discovery company affiliated with publicly listed Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 00056597000, German Prime Standard). NEMOD´s development program focuses on oncological indications like gastric, colon, liver, and breast cancer. Thomsen-Friedenreich (abbreviated "TF") is an antigen unique in its specificity as it does solely express on tumor cells. TF can be be found on a variety of solid carcinomas including colon, gastric, pancreatic, lung, breast and ovarian cancer.

The Board of Directors